API | roscovitine

roscovitine Report issue

Small molecule Experimental

AACT ChEMBL MeSH PubChem

Active Ingredient History

NOW

Seliciclib is an experimental drug candidate in the family of pharmacological cyclin-dependent kinase (CDK) inhibitors that preferentially inhibit multiple enzyme targets including CDK2, CDK7 and CDK9, which alter the growth phase or state within the cell cycle of treated cells. Seliciclib is being developed by Cyclacel.This is a phase II, dose ranging, multicenter, randomized, double-blind, placebo-controlled study. ^Wikipedia

Chemistry

SMILES: CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1
InChIKey: BTIHMVBBUGXLCJ-OAHLLOKOSA-N
Mol. Mass: 354.46
ALogP: 3.2 Partition coefficient
ChEMBL Molecule:
seliciclib

More Chemistry

Pharmacology

Mechanisms of Action:
- Cyclin-dependent kinase 1 (Homo sapiens) ^UniProt
- Cyclin-dependent kinase 2 (Homo sapiens) ^UniProt
- Cyclin-dependent-like kinase 5 (Homo sapiens) ^UniProt
- Cyclin-dependent kinase 7 (Homo sapiens) ^UniProt
- Cyclin-dependent kinase 9 (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

2-(1-ethyl-2-hydroxyethylamino)-6-benzylamino-9-isopropylpurine | (2r)-2-((6-benzylamino-9-(propan-2-yl)-9h-purin-2-yl)amino)butan-1-ol | al-39256 | cyc202 | cyc 202 | cyc-202 | roscovitine | r-roscovitine | seliciclib

Organizations (10)

Research & Development (10)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (8)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (8)

Breast Neoplasms (Phase 1)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Cushing Syndrome (Phase 2)

Cystic Fibrosis (Phase 2)

Glaucoma, Open-Angle (Phase 2)

Neoplasms (Phase 1)

Ocular Hypertension (Phase 2)

Pituitary ACTH Hypersecretion (Phase 2)

Overview

Highest Phase: Phase 2
# of Trials: 7
# of Trial Organizations: 10

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue